Eltrombopag for Lower-risk MDS With Severe Thrombocytopenia

Share this content:
Eltrombopag was well-tolerated, significantly raised platelet counts, and reduced bleeding events among patients with MDS and severe thrombocytopenia.
Eltrombopag was well-tolerated, significantly raised platelet counts, and reduced bleeding events among patients with MDS and severe thrombocytopenia.

Eltrombopag was well-tolerated, significantly improved platelet counts, and reduced bleeding events among patients with lower-risk myelodysplastic syndromes (MDS) and severe thrombocytopenia, according to a study published in The Lancet Haematology.1

Among patients with MDS, the presence of thrombocytopenia increases the risk of death, but treatments in this setting are limited. Researchers evaluated whether eltrombopag, a thrombopoietin receptor agonist, improves thrombocytopenia among patients with lower-risk disease.

For the first phase of the single-blind, phase 2 superiority trial (EQoL-MDS; EudraCT Identifier: 2010-022890-33), investigators enrolled 90 adults patients with low-risk or International Prognostic Scoring System intermediate-1-risk MDS and severe thrombocytopenia.

Participants were randomly assigned 2:1 to receive eltrombopag at varying doses or placebo for at least 24 weeks until disease progression or unacceptable toxicity.

An interim analysis showed that 47% of the 59 patients in the eltrombopag arm achieved platelet response compared with 3% of the 31 patients in the placebo arm.

In the eltrombopag group, 14% had bleeding events vs 42% in the placebo group. There was no significant difference in the rate of progression to acute myeloid leukemia or disease progression between the 2 treatment arms.

RELATED: Cord-blood Transplant Donations Improve Survival of Patients With Acute Leukemia or Myelodysplastic Syndrome

Nearly half (46%) of patients who received eltrombopag had grade 3 to 4 adverse events compared with 16% of those in the placebo group.

Additional analyses assessing the impact of eltrombopag on survival and its long-term safety in this population are ongoing.

Reference

  1. Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017 Feb 2. doi: 10.1016/S2352-3026(17)30012-1 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters